Lung Cancer Dispatch
Follow
Find tag "etoposide"
3.9K views | +1 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Chemo Combo Increases Survival, Toxicity in Sensitive Relapsed SCLC

Chemo Combo Increases Survival, Toxicity in Sensitive Relapsed SCLC | Lung Cancer Dispatch | Scoop.it

"Cisplatin, etoposide, and irinotecan outperformed topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC) in a Japanese trial, though there was substantially increased toxicity with the regimen.


“ 'Topotecan is the only drug approved in the United States and the European Union for relapsed SCLC,' said Koichi Goto, MD, PhD, of the National Cancer Center Hospital East in Chiba, Japan. He presented results of the new trial at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Sensitive relapse refers to cancers that respond to initial chemotherapy and relapse more than 3 months after completion of that therapy, while refractory cancers do not respond initially or relapse within that 3 month window."


Editor's note: This story is about a clinical trial with volunteer patients to test a new treatment for small cell lung cancer (SCLC). The new treatment is specifically for people with SCLC who were treated with chemotherapy successfully, but whose cancer returned more than 3 months after chemo—this is known as "sensitive relapsed SCLC." The new treatment combines three chemo drugs: cisplatin, etoposide, and irinotecan. In the clinical trial, some patients took the chemo combo and some were treated with the chemo drug topotecan, which is a standard treatment for the condition. Patients who took the new treatment lived longer, but they had more toxic side effects than the patients who took topotecan.

Cancer Commons's insight:

Cancer Network  |  Jun 23, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer

IMGN901 Demonstrates No Significant Benefit, Possible Harm in Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

The makers of lorvotuzumab mertansine (IMGN901) have halted a clinical trial investigating the use of the drug in extensive-stage small-cell lung cancer (SCLC). An independent monitoring group recommended ending the trial because patients treated with IMGN901 in addition to the chemotherapy agents etoposide (Etopophos) and carboplatin (Paraplatin) fared no better than patients treated with Etopophos and Paraplatin only. Furthermore, the patient group receiving IMGN901 appeared to have higher rates of infections and infection-related deaths, with at least one death potentially related to IMGN901.

Cancer Commons's insight:

Yahoo! Finance | Nov 5, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Pilot Study of New SCLC Drug Offers Encouragement

Preliminary trial results indicate that a new drug, IMGN901, enhances standard etoposide/carboplatin treatment in some small cell lung cancer (SCLC) patients. IMGN901 targets cells that express the protein CD56—a hallmark of nearly all SCLC tumors. ImmunoGen, Inc. will further investigate the SCLC treatment potential of IMGN901 in the large-scale NORTH trial.

Cancer Commons's insight:

equities.com | Sep 11, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Clinical Trial for SCLC Now Enrolling Patients

New Clinical Trial for SCLC Now Enrolling Patients | Lung Cancer Dispatch | Scoop.it

While medical research has produced significant treatment innovations for many cancer types, so far little has changed for small cell lung cancer (SCLC). Current treatment guidelines recommend chemotherapy with etoposide (Etopophos) and cisplatin (Platinol), drugs than are more than 30 years old. Relapse is common, and survival rates remain low. Now, the new  PINNACLE clinical trial will investigate a new drug against SCLC. Patients with extensive-stage SCLC who have never received any other cancer treatment will be treated with Etopophos and Platinol either by themselves or in combination with the new drug, OMP-59R5. The drug acts by inhibiting NOTCH, a protein involved in cell development and growth that plays a role in various cancers. For more information, call 646-888-4203.

Cancer Commons's insight:

ScienceDaily | Nov 13, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Pomalidomide Can Be Safely Added to Chemotherapy in Small Cell Lung Cancer

In a recent phase I/IIa study, patients with extensive-stage small cell lung cancer (SCLC) that had not previously been treated were given a drug called pomalidomide. The treatment was combined with standard chemotherapy consisting of cisplatin (Platinol) and etoposide (Etopophos/Toposar). Pomalidomide appeared to be safe, with a maximum tolerated dose of 4 mg/day. However, it did not appear to increase the efficacy or decrease the toxicity of the chemotherapy.

Cancer Commons's insight:

Journal of Thoracic Oncology | Jan 30, 2013

more...
No comment yet.